GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT07140289

Enrolling by invitation

Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) on Gastric Emptying

The Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) on Gastric Emptying Before Elective Surgery

Lead sponsor

Wael Saasouh, MD

Asset

GLP-1 / incretin class catch-all

Listed sites

Recruiting sites

—

Enrollment

100

estimated

Study population

Perioperative / gastric aspiration risk

Key I/E criterion

—

Primary endpoint

•Gastric cross-sectional area

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07140289

Org study IDIRB 23-10-6273

Timeline

Milestones

Study first posted2025-08-24actual

Study start2025-09-01estimated

Last update posted2025-09-03actual

Primary completion2027-06-01estimated

Study completion2028-06-01estimated

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Perioperative / gastric aspiration risk

Eligibility

Who can enroll

Minimum age18 Years

Maximum age90 Years

SexAll

Healthy volunteersAccepted

Sampling methodNon probability sample

Study population text

Surgical patients undergoing procedures at the Detroit Medical Center

Inclusion criteria

•Adult patients who are receiving Glucagon-like peptide-1 Receptor Agonist medication and scheduled for any elective surgery or procedure under anesthesia.

•The patient has provided informed consent for the study

Exclusion criteria

•Pregnant patients

•Patients with abnormal gastric anatomy like previous gastric resection or bypass( gastric band in situ, previous fundoplication, hiatus hernia

•Inability to consent

•Emergency surgery

•Cognitive impairment (due to the mixed reasons of potential misunderstanding of the aim of the study and inability to provide informed consent, potential inability to provide detailed fasting regimen before the surgery, potential for impaired use of GLP-1 agonists before the surgery)

•Terminal illness (due to the effect of chronic illness on the physiologic functions of gastrointestinal tract and gastric emptying)

Endpoints (12)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK

Other clinical outcomes

Cardiovascular outcomes

1 endpoint

Secondary/protocol endpoint

Mortality

Time frame:Within 30 days of surgery (if data is available)

All-cause death

time to event, event

SNOMED 419620001

Safety / tolerability / PK

6 endpoints

Secondary/protocol endpoint

Incidence of Pulmonary Aspiration

Time frame:Between induction of anesthesia and discharge (up to 4 hours) from the post-anesthesia care unit after surgery

event count, event

Secondary/protocol endpoint

Incidence of Aspiration Pneumonia/Pneumonitis

Time frame:Within 7 days of surgery (if data is available)

time to event, event

Secondary/protocol endpoint

Need for Reintubation

Time frame:Within 7 days of surgery (if data is available)

time to event, event

Secondary/protocol endpoint

Other Medical Complications

Time frame:Within 7 days of surgery (if data is available)

composite event, event

Secondary/protocol endpoint

Hypoxemia

Time frame:Between emergence from anesthesia and discharge from the post-anesthesia care unit after surgery

categorical status, event

Secondary/protocol endpoint

Reintubation or Unplanned Airway Intervention

Time frame:Within 7 days of surgery (if data is available)

event count, event

Other clinical outcomes

5 endpoints

Primary/protocol endpoint

Gastric cross-sectional area

Time frame:Preoperatively on the day of surgery (between admission to preoperative testing and start of surgical procedure).

descriptive

Secondary/protocol endpoint

Incidence of other Respiratory Complications

Time frame:Within 7 days of surgery (if data is available)

event count, event

Secondary/protocol endpoint

ICU Length of Stay

Time frame:Up to hospital discharge (up to 30 Days)

descriptive

Secondary/protocol endpoint

Hospital Length of Stay

Time frame:Up to 30 days

descriptive

Secondary/protocol endpoint/low confidence

Postoperative Anesthetic Respiratory Complications

Time frame:Between emergence from anesthesia and discharge from the post-anesthesia care unit after surgery

composite event, event

componentslaryngospasm, bronchospasm, upper airway obstruction, noninvasive ventilation requirement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.